Paz Collado

Paz Collado

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2018 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
PCPaz Collado
Paz Collado
DWD. Windschall
D. Windschall
JVJelena Vojinovic
Jelena Vojinovic
SMS. Magni-Manzoni
S. Magni-Manzoni
PBP. Balint
P. Balint
ENE. Naredo
E. Naredo
Recently preliminary ultrasonography (US) definitions, in B mode, for normal components of pediatric joints have been developed by the OMERACT US group. The aim of the current study was to include Doppler findings in the evaluation and definition of normal joint features that can be visualized in healthy children at different age groups. A multistep approach was used. Firstly, new additional definitions of joint components were proposed during an expert meeting. In the second step, these definitions, along with the preliminary B-mode-US definitions, were tested for feasibility in an exercise in healthy children at different age groups. In the last step, a larger panel of US experts were invited to join a web-based consensus process in order to approve the developed definitions using the Delphi methodology. A Likert scale of 1–5 was used to assess agreement. Physiological vascularity and fat pad tissue were identified and tested as two additional joint components in healthy children. Since physiological vascularity changes over the time in the growing skeleton, the final definition of Doppler findings comprised separate statements instead of a single full definition. A total of seven statements was developed and included in a written Delphi questionnaire to define and validate the new components. The final definitions for fat pad and physiological vascularity agreed by the group of experts reached 92.9% and 100% agreement respectively in a web survey. The inclusion of these two additional joints components which are linked to detection of Doppler signal in pediatric healthy joints will improve the identification of abnormalities in children with joint pathologies.

1 July 2018 in Reumatología Clínica
Verified
Journal Article
Closed access
PCPaz Collado
Paz Collado
AKAml Kelada
Aml Kelada
MCMaria Cámara
Maria Cámara
AZAndrew Zeft
Andrew Zeft
AFAron Flagg
Aron Flagg

26 June 2023 in Arthritis Care & Research
Verified
Journal Article
Closed access
PCPaz Collado
Paz Collado
MMMaría Victoria Martire
María Victoria Martire
SLStefano Lanni
Stefano Lanni
OLOrazio De Lucia
Orazio De Lucia
PBPeter Balint
Peter Balint
FGfor the OMERACT Ultrasound Group
for the OMERACT Ultrasound Group

1 August 2016 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
PCPaz Collado
Paz Collado
CMClara Malattia
Clara Malattia

Verified
Journal Article
Open access
PDF file
JBJoao Carlos Batista-Liz
Joao Carlos Batista-Liz
VCVanesa Calvo-Río
Vanesa Calvo-Río
MMMaría Sebastián Mora-Gil
María Sebastián Mora-Gil
BSBelén Sevilla-Pérez
Belén Sevilla-Pérez
AMAna Márquez
Ana Márquez
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
ITGAM–ITGAX (rs11150612, rs11574637), VAV3 rs17019602, CARD9 rs4077515, DEFA (rs2738048, rs10086568), and HORMAD2 rs2412971 are mucosal immune defence polymorphisms, that have an impact on IgA production, described as risk loci for IgA nephropathy (IgAN). Since IgAN and Immunoglobulin-A vasculitis (IgAV) share molecular mechanisms, with the aberrant deposit of IgA1 being the main pathophysiologic feature of both entities, we assessed the potential influence of the seven abovementioned polymorphisms on IgAV pathogenesis. These seven variants were genotyped in 381 Caucasian IgAV patients and 997 matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of these seven polymorphisms when the whole cohort of IgAV patients and those with nephritis were compared to controls. Similar genotype and allele frequencies of all polymorphisms were disclosed when IgAV patients were stratified according to the age at disease onset or the presence/absence of gastrointestinal or renal manifestations. Likewise, no ITGAM–ITGAX and DEFA haplotype differences were observed when the whole cohort of IgAV patients, along with those with nephritis and controls, as well as IgAV patients, stratified according to the abovementioned clinical characteristics, were compared. Our results suggest that mucosal immune defence polymorphisms do not represent novel genetic risk factors for IgAV pathogenesis.

22 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JLJoao Carlos Batista Liz
Joao Carlos Batista Liz
FGFernanda Genre
Fernanda Genre
VCVerónics Pulito Cueto
Verónics Pulito Cueto
SRSara Remuzgo-Martínez
Sara Remuzgo-Martínez
DPDiana Prieto-Peña
Diana Prieto-Peña
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV.